Regulatory approvals ind:hc:talzenna:1
Regulatory approval
Published by the Health Canada .
Approved
TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
This is written in the approval
document .
Citation
Pfizer Canada ULC. Talzenna (talazoparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083453.PDF. Revised February 2026. Accessed April 2026.
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
1 organization
Cancer types
1 cancer type
Organizations
Biomarkers
Cancer types
Therapies
HC (1)
BRCA1 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
BRCA1 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
BRCA2 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
BRCA2 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
ATM pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
ATM oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
ATR oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
CDK12 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
ATR pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
FANCA oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
CHEK2 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
CHEK2 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
FANCA pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
MLH1 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
PALB2 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
PALB2 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
MLH1 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
MRE11 oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
RAD51C pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
RAD51C oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
MRE11 pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
NBN oncogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
HC (1)
NBN pathogenic variants
Prostate Adenocarcinoma
Enzalutamide ,
Talazoparib
Contributions
Date
Contributor
Description
2024-10-30
Van Allen lab
Initial access of FDA approvals